



ANNUAL MEETING

21st September 2014 - Siena, Italy

NH Excelsior, Piazza La Lizza - Siena, Italy

AGENDA

09.00-09.30 General Assembly & Coordinator address

Marc Feldmann - Kennedy Institute, University of Oxford, UK

WP-LEADER LED SYMPOSIUM (introduced and chaired by each WP leader)

09.30-10.20 WP1: Discovery of key regulatory nodes within SL biosynthesis in patients with coronary artery diseases via Flux methodologies

Reijo Laaksonen & Kim Ekroos - Zora Biosciences OY, Finland (WP leader)

Katriina Aalto-Setälä - University of Tampere, Finland

10.20-10.50 *Coffee break*

10.50-11.40 WP2: Genome-scale RNAi screening to reveal rate-limiting pathways in ceramide metabolism and signalling

Birte Sönnichsen - Cenix BioScience GmbH, Germany (WP leader)

Christer Ejsing - Syddansk Universitet, Denmark

11.40-12.30 WP3: Evaluation of the significance of prospective therapeutic targets within the SL pathway in terms of inflammatory signalling

Zhong-Qun Yan - Karolinska Institutet, Sweden (WP leader)

Tony Futerman - Weizmann Institute of Science, Israel

12.30-14.00 *Lunch*

14.00-14.50 WP4: Evaluation of biodistribution, bioactivity and pro-atherogenic properties of alterations in SL metabolism

Maria Salagianni - Biomedical Research Foundation Academy Of Athens, Greece (WP leader)

Philippe Sansonetti - Institut Pasteur, France

14.50-15.40 WP5: Development of LNA oligonucleotide-based therapeutics targeting SL metabolism and its associated signalling

Marie Wickström Lindholm - Santaris Pharma A/S, Denmark (WP leader)

Claudia Monaco - Kennedy Institute, University of Oxford, UK

15.40-16.00 WP6: Management, Review and Assessment

WP7: Dissemination and Diffusion of project results

Paola Cesaroni - ALTA Ricerca e Sviluppo in Biotecnologie, Italy

16.00-16.30 *Coffee break*

16.30 **AtheroFlux Steering Committee**

